SIShannon Inglet

Shannon Inglet

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Shannon Inglet has a total of 23 co-authors. Here are the top co-authors by number of shared publications:

  • Allison M. Butler

    Statistical Data Center, Intermountain Medical Center, Murray, UT 84107, USA

    1 shared publication
  • Amie H. Quinones

    Department of Pharmacy, Intermountain Medical Center

    1 shared publication
  • Amie Quinones

    Department of Pharmacy, Intermountain Medical Center, Murray, UT 84107, USA; Department of Pharmacy, Layton Hospital, Layton, UT 84041, USA

    1 shared publication
  • Anh Lian

    Intermountain Healthcare, Taylorsville, UT, USA

    1 shared publication
  • Bradly Winter

    Intermountain Healthcare, Taylorsville, UT, USA

    1 shared publication
  • Carolyn Anctil

    Utah Emergency Physicians, Murray, UT 84107, USA

    1 shared publication

Latest Publications

  • Two Years of the COVID-19 Pandemic: What Lessons Have We Learned?

    by Shannon Inglet

    Two years ago, the World Health Organization declared a global pandemic after an outbreak of a novel coronavirus. Since then, unprecedented challenges have shaped a “new normal.” As of early March 2022, more than 6 million lives have been lost globally to COVID-19. But we have learned much over the past 2 years. Some lessons have been heartening, inspiring innovation, and adaptability; others have been devastating and will have reverberating consequences for years to come. The COVID-19 pandemic has taught us lessons that span medical, economic, social, and environmental arenas. And we still have much to learn.


  • Patient utilization of prescription opioids after discharge from the emergency department

    by Ruixin Shi, Amie Quinones, Jeremy Bair, Ramona O. Hopkins, Allison M. Butler, Shannon Inglet, Carolyn Anctil, Jake Woods, Jamison Jones, Joseph R. Bledsoe


  • Clinical Data for the Use of Cannabis-Based Treatments: A Comprehensive Review of the Literature

    by Shannon Inglet, Bradly Winter, Sarah E. Yost, Sophia Entringer, Anh Lian, Meryl Biksacky, Renee D. Pitt, Whitney Mortensen

    Objective: To compile and synthesize the available literature describing medical cannabis use across various disease states. Data Sources: PubMed, EBSCO, and Google Scholar searches were conducted using MeSH and/or keywords. Study Selection and Data Extraction: Studies were included if they described the use of cannabis-based products and medications in the treatment of a predefined list of disease states in humans and were published in English. The extraction period had no historical limit and spanned through April 2019. Data Synthesis: Evidence was compiled and summarized for the following medical conditions: Alzheimer disease, amyotrophic lateral sclerosis, autism, cancer and cancer-associated adverse effects, seizure disorders, human immunodeficiency virus, inflammatory bowel disease, multiple sclerosis (MS), nausea, pain, posttraumatic stress disorder, and hospice care. Relevance to Patient Care and Clinical Practice: Based on identified data, the most robust evidence suggests that medical cannabis may be effective in the treatment of chemotherapy-induced nausea and vomiting, seizure disorders, MS-related spasticity, and pain (excluding diabetic neuropathy). Overall, the evidence is inconsistent and generally limited by poor quality. The large variation in cannabis-based products evaluated in studies limits the ability to make direct comparisons. Regardless of the product, a gradual dose titration was utilized in most studies. Cannabis-based therapies were typically well tolerated, with the most common adverse effects being dizziness, somnolence, dry mouth, nausea, and euphoria. Conclusions: As more states authorize medical cannabis use, there is an increasing need for high-quality clinical evidence describing its efficacy and safety. This review is intended to serve as a reference for clinicians, so that the risks and realistic benefits of medical cannabis are better understood.


  • Open Access

    Seizure Prophylaxis in Patients with Traumatic Brain Injury: A Single-Center Study

    by Shannon Inglet, Margaret Baldwin, Amie H. Quinones, Sarah Majercik, Dave S. Collingridge, Joel MacDonald

    The use of prophylactic anticonvulsants to prevent early post-traumatic seizures (PTSs) is recommended but inconsistently employed in patients with traumatic brain injury (TBI). The authors evaluated outcomes associated with prophylaxis administration in patients with TBI at a Level 1 trauma center. All patients admitted with TBI from October 2007 through May 2012 were included. Our primary outcome was the incidence of early PTSs. Secondary outcomes included mortality, length of hospital and intensive care unit (ICU) stays, and incidence of late seizures. Of the 2,111 patients with TBI, 557 (26.4%) received seizure prophylaxis and 1,554 (73.6%) did not. Two early PTSs occurred in the prophylaxis group (0.4%), whereas 21 occurred in the non-prophylaxis group (1.4%) (p = 0.05). The overall mortality rate was higher in patients who received prophylaxis (14.2% vs. 6.2%; p < 0.001), and the mean hospital length of stay (LOS) was longer (6.8 ± 6.9 vs. 3.8 ± 5 days; p < 0.001). In patients with severe and moderate TBI, the rate of prophylaxis administration was approximately half, whereas significantly fewer patients with mild TBI received prophylaxis than did not (20.2% vs 79.8%, p < 0.001). Lower Glasgow Coma Scale (GCS) score and longer hospital LOS were associated with early PTS (p = 0.008 for both comparisons), but sex and age were not. Brain hemorrhage was present in 78.3% of those patients who experienced early seizures. In our cohort, patients who received seizure prophylaxis had a lower GCS score, higher overall mortality rate, longer LOS, and more frequent ICU admissions, suggesting that patients who received prophylaxis were likely more severely injured.